94
Participants
Start Date
May 20, 2021
Primary Completion Date
June 14, 2022
Study Completion Date
January 9, 2023
AK002
Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
Placebo
Placebo
Allakos Investigational Site, Great Neck
Allakos Investigational Site, Fredericksburg
Allakos Investigational Site, Durham
Allakos Investigational Site, Concord
Allakos Investigational Site, Greenwood
Allakos Investigational Site, Ponte Vedra
Allakos Investigational Site, Edgewater
Allakos Investigational Site, Jacksonville
Allakos Investigational Site, Brandon
Allakos Investigational Site, Lakewood Rch
Allakos Investigational Site, New Port Richey
Allakos Investigational Site, Kissimmee
Allakos Investigational Site, Birmingham
Allakos Investigational Site, Hermitage
Allakos Investigational Site, Hixson
Allakos Investigational Site, Chattanooga
Allakos Investigational Site, Mentor
Allakos Investigational Site, Cincinnati
Allakos Investigational Site, Cincinnati
Allakos Investigational Site, Dayton
Allakos Investigational Site, Crowley
Allakos Investigational Site, Southlake
Allakos Investigational Site, Fort Worth
Allakos Investigational Site, Webster
Allakos Investigational Site, San Antonio
Allakos Investigational Site, Cedar Park
Allakos Investigational Site, Austin
Allakos Investigational Site, Lubbock
Allakos Investigational Site, Wheat Ridge
Allakos Investigational Site, Sandy City
Allakos Investigational Site, Salt Lake City
Allakos Investigational Site, Ogden
Allakos Investigational Site, Gilbert
Allakos Investigational Site, Reno
Allakos Investigational Site, Lomita
Allakos Investigational Site, Chula Vista
Allakos Investigational Site, Bristol
Allakos Investigational Site, Hamden
Allakos Investigational Site, Florham Park
Lead Sponsor
Allakos Inc.
INDUSTRY